Cerenome Stock-Based Compensation Growth & History (CNSY)

Cerenome's stock-based compensation was $1.5M for fiscal 2025.

View full Cerenome company overview

Cerenome annual stock-based compensation history

Cerenome annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31$1.5M$990,000+180.00%
20242024-12-31$550,000−$19,000−3.34%
20232023-12-31$569,000−$37,000−6.11%
20222022-12-31$606,000$00.00%
20212021-12-31$606,000$359,000+145.34%
20202020-12-31$247,000$120,000+94.49%
20192019-12-31$127,000−$228,000−64.23%
20182018-12-31$355,000−$398,000−52.86%
20172017-12-31$753,000−$327,000−30.28%
20162016-12-31$1.1M−$961,000−47.08%
20152015-12-31$2.0M−$1.1M−34.18%
20142014-12-31$3.1M−$507,000−14.05%
20132013-12-31$3.6M−$296,000−7.58%
20122012-12-31$3.9M$588,000+17.73%
20112011-12-31$3.3M$261,000+8.54%
20102010-12-31$3.1M$406,000+15.33%
20092009-12-31$2.6M

Cerenome stock-based compensation trends

Over the last five fiscal years, Cerenome's stock-based compensation increased from $247,000 to $1.5M, a change of $1.3M. The latest reported quarter, Q2 2026, shows $830,000.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cerenome source filings ↗

Community posts

It’s quiet here.

No posts about CNSY yet. Start the conversation.

Write the first post